The FDA approved the first oral treatment for breast cancer patients who have inherited mutations in their BRCA genes. Susan Domchek, MD, who was involved in the clinical trial, discusses how this is a major step forward.
Penn Medicine Magazine
Penn Medicine Magazine's latest issue includes the story of how the Basser Center was founded in memory of Faith Basser, and how BRCA mutations can impact families around the world.
The U.S. Food and Drug Administration recently approved olaparib as the first treatment for advanced breast cancer caused by mutations in BRCA genes, in an important step in the fight against inherited cancers.
Susan Domchek, MD, Executive Director of the Basser Center, discussed the evolving treatment landscape for patients with BRCA-related, metastatic breast cancer.
Last week, journalist Joan Lunden moderated a panel of experts, “Knowledge is Power: Understanding and Managing BRCA-Related Cancer Risk.” The program, co-presented by the Basser Center, focused on the latest lifesaving information surrounding BRCA-related cancers.
Basser Center co-founder Mindy Gray's family is in the news, thanks to her inspiring father, Phil Basser, whose love of the Eagles has gone viral just before his 100th birthday.
OncLive reports on recent Penn-led research showing that the combination of olaparib and durvalumab demonstrated a disease control rate of 80 percent for pretreated patients with germline BRCA-mutated, HER2- negative metastatic breast cancer.
Good Morning America
TeloYears is an at-home test that promises to reveal a user's true biological age by measuring telomeres, the ends of chromosomes that wear down over time. Susan Domchek, MD, advised caution, saying there has to be more study.
The biennial Basser Jean Bash celebrated five years of progress toward understanding, treating and preventing hereditary cancers. The benefit honored Raquel and Michael Hass and Pulitzer Prize-winning author Siddhartha Mukherjee, MD, DPhil.
Basser's Angela Bradbury, MD, says one of the biggest challenges is that many patients don't have access to genetic counselors.
Forbes takes a deep dive into the use of PARP inhibitors in the fight against pancreatic cancer, which features a recently opened trial led by Kim A. Reiss Binder, MD, an assistant professor of Hematology Oncology.
A local woman and her family discuss how they have been affected by cancers caused by a PALB2 gene mutation, a gene that works to repair broken strands of DNA. Like BRCA, it potentially increases an individual's risk of certain cancers.
CURE Magazine discusses the complicated issue of genetic testing, with input from the experts on the Basser Center's April 25th panel in Manhattan, which included Executive Director, Dr. Susan Domchek.
Immunotherapy treatments are on the rise. The Abramson Cancer Center's Dr. Robert Vonderheide, in collaboration with the Basser Center, is leading vaccine-based trials for the prevention of cancers associated with BRCA gene mutations.
Penn Medicine News
At the American Society of Clinical Oncology Annual Meeting, an international team of scientists presented the results of the phase III OlympiAD trial demonstrating for the first time that olaparib is superior to chemotherapy in patients with BRCA-related advanced breast cancer.
A new $21 million gift to the Basser Center from Penn alumni Mindy and Jon Gray will cement and propel Penn’s preeminence as a leader in research to improve treatment and prevention strategies for hereditary cancers.
Getting together with relatives can be the perfect opportunity to discuss your family medical history. Basser Center genetic counselors Danielle McKenna, Amanda Brandt, and Dana Clark discuss how best to approach the topic.
An article from the Toronto Star profiles Steven Narod, MD, FRCPC, FRSC, director of the Familial Breast Cancer Research Unit and a senior scientist at the Women’s College Hospital in Toronto, whose seminal work on BRAC earned him this year's Basser Global Prize.